Singapore, May 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and E... Read More
Singapore, May 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and T... Read More
Singapore, May 3 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined... Read More
Singapore, May 3 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post... Read More
Singapore, May 3 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) ... Read More
Singapore, May 3 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) ... Read More
Singapore, May 3 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy... Read More
Singapore, May 3 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy... Read More
Singapore, May 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety ... Read More
Singapore, May 3 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Mon... Read More